BIIB147 for ALS

(HORIZON Trial)

This trial tests the safety of a new drug, BIIB147, for people with amyotrophic lateral sclerosis (ALS). ALS progressively damages nerve cells in the brain and spinal cord, causing problems with movement, speaking, and breathing. Participants will receive either the study drug or a placebo through a spinal injection, and researchers will monitor any health issues. Eligible participants should have ALS without certain genetic variants and should not require mechanical breathing assistance for most of the day. The study aims to determine how the body reacts to the drug and its potential to slow the disease's progression. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.

In a previous study, researchers did not find clear safety evidence for BIIB147 because this is the first time it is being tested in humans. Therefore, no earlier studies show its safety.

Since this study is in the early stages, the main goal is to assess how well participants tolerate BIIB147 and identify any side effects. Early-stage trials typically involve a small number of people, allowing researchers to closely monitor for any health problems or serious issues.

Most treatments for ALS, like Riluzole and Edaravone, aim to slow disease progression by reducing nerve damage. But BIIB147 works differently, targeting the underlying mechanisms of neurodegeneration in ALS with potentially novel pathways. Researchers are excited because BIIB147 could offer a new approach, possibly altering disease progression more effectively than current therapies. This could mean better outcomes for patients with ALS, offering hope for improved quality of life.

Research into BIIB147 for amyotrophic lateral sclerosis (ALS) remains in the early stages, so direct evidence of its effectiveness in humans is not yet available. This trial will evaluate different doses of BIIB147, with participants in various treatment arms receiving either Dose A, B, C, or D of BIIB147 or a placebo. The treatment targets motor neurons, the cells affected by ALS, and aims to slow the disease's progression by possibly protecting or repairing these neurons. Early lab studies suggest that similar methods might improve the survival and function of these neurons. While these initial signs are promising, more research is needed to understand how BIIB147 works in people with ALS.⁶⁷⁸⁹¹⁰